Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends (Q39022532)

8 September 2017

title

Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends (English)

1 reference

8 September 2017

0 references

3

1 reference

8 September 2017

Sergey O Bachurin

1

1 reference

8 September 2017

Elena V Bovina

series ordinal

2

1 reference

8 September 2017

publication date

13 January 2017

1 reference

Medicinal Research Reviews

8 September 2017

published in

1 reference

8 September 2017

volume

37

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

1186-1225

1 reference

Alzheimer's disease drug-development pipeline: few candidates, frequent failures

8 September 2017

cites work

1 reference

Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer's disease

21 January 2018

1 reference

Alzheimer disease: a tale of two prions

21 January 2018

1 reference

The multifactorial nature of Alzheimer's disease for developing potential therapeutics.

21 January 2018

1 reference

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

21 January 2018

1 reference

The Revitalized Tau Hypothesis on Alzheimer's Disease

21 January 2018

1 reference

What causes alzheimer's disease?

21 January 2018

1 reference

21 January 2018

1 reference

Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo

21 January 2018

1 reference

Screening for the beta-amyloid precursor protein mutation (APP717: Val----Ile) in extended pedigrees with early onset Alzheimer's disease.

21 January 2018

1 reference

A familial Alzheimer's disease locus on chromosome 1.

21 January 2018

1 reference

Function and dysfunction of the presenilins

21 January 2018

1 reference

Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau

21 January 2018

1 reference

Structural characterization of the core of the paired helical filament of Alzheimer disease

21 January 2018

1 reference

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

21 January 2018

1 reference

Alzheimer's disease: a central role for amyloid

21 January 2018

1 reference

Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs

21 January 2018

1 reference

A beta oligomers - a decade of discovery

21 January 2018

1 reference

21 January 2018

1 reference

Mitochondrial dysfunction: cause and consequence of Alzheimer's disease

21 January 2018

1 reference

Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions

21 January 2018

1 reference

Amyloid Fibres: Inert End-Stage Aggregates or Key Players in Disease?

21 January 2018

1 reference

Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease

21 January 2018

1 reference

Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.

21 January 2018

1 reference

Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action

21 January 2018

1 reference

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections

21 January 2018

1 reference

Neurobiology of Alzheimer's disease

21 January 2018

1 reference

Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor

21 January 2018

1 reference

Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons

21 January 2018

1 reference

Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.

21 January 2018

1 reference

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

21 January 2018

1 reference

Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing

21 January 2018

1 reference

Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases

21 January 2018

1 reference

Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease

21 January 2018

1 reference

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

21 January 2018

1 reference

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial

21 January 2018

1 reference

Targeting the β secretase BACE1 for Alzheimer's disease therapy

21 January 2018

1 reference

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

21 January 2018

1 reference

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

21 January 2018

1 reference

Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01

21 January 2018

1 reference

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

Transthyretin amyloidoses: New strategies for therapeutic intervention

21 January 2018

1 reference

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

21 January 2018

1 reference

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

21 January 2018

1 reference

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

21 January 2018

1 reference

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease

21 January 2018

1 reference

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease

21 January 2018

1 reference

21 January 2018

1 reference

Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

21 January 2018

1 reference

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

21 January 2018

1 reference

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study

21 January 2018

1 reference

Nicotinic Acetylcholine Receptors in the Pathophysiology of Al zheimer's Disease: The Role of Protein-Protein Interactions in Current and Future Treatment

21 January 2018

1 reference

Glutamate transmission and toxicity in Alzheimer's disease

21 January 2018

1 reference

Protein S-Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases

21 January 2018

1 reference

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy

21 January 2018

1 reference

Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

21 January 2018

1 reference

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

21 January 2018

1 reference

Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases

21 January 2018

1 reference

Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments

21 January 2018

1 reference

Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

21 January 2018

1 reference

Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease

21 January 2018

1 reference

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model

21 January 2018

1 reference

Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer's disease

21 January 2018

1 reference

Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression

21 January 2018

1 reference

Systemic administration of riluzole enhances recognition memory and facilitates extinction of fear memory in rats

21 January 2018

1 reference

The glutamate hypothesis in ALS: pathophysiology and drug development.

21 January 2018

1 reference

Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype

21 January 2018

1 reference

Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.

21 January 2018

1 reference

Amyloid-cholinesterase interactions. Implications for Alzheimer's disease

21 January 2018

1 reference

Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice

21 January 2018

1 reference

Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

21 January 2018

1 reference

Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice

21 January 2018

1 reference

Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials

21 January 2018

1 reference

Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile x mice

21 January 2018

1 reference

Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system.

21 January 2018

1 reference

Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats

21 January 2018

1 reference

Effects of the neurotrophic agent T-817MA on oligomeric amyloid-β-induced deficits in long-term potentiation in the hippocampal CA1 subfield

21 January 2018

1 reference

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

21 January 2018

1 reference

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

21 January 2018

1 reference

Tolerability, safety and pharmacokinetics of the FGLL peptide, a novel mimetic of neural cell adhesion molecule, following intranasal administration in healthy volunteers.

21 January 2018

1 reference

Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease

21 January 2018

1 reference

Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability

21 January 2018

1 reference

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After

21 January 2018

1 reference

Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial

21 January 2018

1 reference

The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function

21 January 2018

1 reference

Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics

21 January 2018

1 reference

Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

21 January 2018

1 reference

Ameliorating effects of HX106N, a water-soluble botanical formulation, on Aβ25-35-induced memory impairment and oxidative stress in mice.

21 January 2018

1 reference

Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma.

21 January 2018

1 reference

Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

21 January 2018

1 reference

Resveratrol, a neuroprotective supplement for Alzheimer's disease.

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

21 January 2018

1 reference

Syntheses And Evaluation Of Asymmetric Curcumin Analogues As Potential Multifunctional Agents For The Treatment Of Alzheimer's Disease

21 January 2018

1 reference

Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease

21 January 2018

1 reference

Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors

21 January 2018

1 reference

Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose

21 January 2018

1 reference

Lack of support for bexarotene as a treatment for Alzheimer's disease

21 January 2018

1 reference

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

21 January 2018

1 reference

Tamibarotene: a candidate retinoid drug for Alzheimer's disease

21 January 2018

1 reference

Influence of isotretinoin on hippocampal-based learning in human subjects

21 January 2018

1 reference

Retinoids for treatment of Alzheimer's disease

21 January 2018

1 reference

Cognitive effects of statin medications

21 January 2018

1 reference

Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin

21 January 2018

1 reference

Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease

21 January 2018

1 reference

Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits.

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

21 January 2018

1 reference

Statins for Treating Alzheimer's Disease: Truly Ineffective?

21 January 2018

1 reference

Therapeutic strategies for Alzheimer's disease in clinical trials.

21 January 2018

1 reference

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.

21 January 2018

1 reference

An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease.

21 January 2018

1 reference

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.

21 January 2018

1 reference

Advances in Psychopharmacology for Anxiety Disorders

21 January 2018

1 reference

Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease?

21 January 2018

1 reference

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

21 January 2018

1 reference

Drug repositioning for Alzheimer's disease.

21 January 2018

1 reference

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

21 January 2018

1 reference

Developing pharmacological therapies for Alzheimer disease

21 January 2018

1 reference

The Potential of Proteomics in Understanding Neurodegeneration.

21 January 2018

1 reference

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.21434

1 reference

8 September 2017

1 reference